Belatacept Injection
Belatacept is an immunosuppressant injection used to help prevent organ rejection in adults who have received a kidney transplant.
🧬 Where this information comes from Click to expand
The clinical label records used on this page are FDA-filed Structured Product Labeling (SPL) retrieved through openFDA. We identified 1 clinical label set within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. Forms, routes, brands, labelers, strengths, and NDC product-record counts are built separately from matching FDA National Drug Code Directory records. The linked DailyMed document is a representative official source for verification, not the page’s only clinical source. View the linked label on DailyMed →
⚠️ FDA Boxed Warning — the FDA’s strongest safety alert ▾
Nulojix carries a serious FDA boxed warning about three major risks: a rare but dangerous lymphoma, other cancers, and life-threatening infections.
Patients treated with Nulojix have a higher-than-normal chance of developing post-transplant lymphoproliferative disorder (PTLD) — an abnormal growth of lymph cells that most often affects the brain. People who have never been exposed to the Epstein-Barr virus (EBV) are at the greatest risk; this is why Nulojix must not be used in anyone who tests negative for EBV or whose EBV status is unknown. Watch for new or worsening changes in thinking, memory, behavior, or personality and report them immediately.
Because this drug lowers immune defenses, it also raises the risk of serious infections and other malignancies (cancers). Only transplant physicians experienced in immunosuppressive therapy should prescribe it, and patients must be monitored at facilities equipped to manage these risks. Nulojix is not recommended for liver transplant patients due to an increased risk of losing the transplanted organ and death.
📖 Belatacept Injection: Patient Information Guide
A plain-language walkthrough of Belatacept Injection — what it treats, how it works, how it’s taken, side effects, warnings and interactions. Tap any section to expand it.
🎯What it's used for▾
Belatacept injection is used to prevent organ rejection after transplant surgery. Currently, only one brand — Nulojix — is approved, and it is given by intravenous infusion.
- Nulojix is approved to prevent kidney rejection in adult kidney transplant recipients
- Nulojix is used in combination with basiliximab induction therapy, mycophenolate mofetil, and corticosteroids — not as a standalone treatment
- Nulojix is approved only for patients who test positive for prior Epstein-Barr virus (EBV) exposure — it is contraindicated in EBV-negative patients or those with unknown EBV status
- Use of Nulojix for organs other than the kidney has not been established, and it is not recommended for liver transplant patients due to higher rates of graft loss and death
⚙️How it works▾
Belatacept is a selective T cell costimulation blocker. T cells are immune cells that play the central role in attacking and rejecting a transplanted organ. To become fully activated, T cells need two signals — and belatacept blocks one of them by binding to proteins called CD80 and CD86 on the surface of antigen-presenting cells (cells that show the immune system what to attack). Without that second signal through CD28, T cells cannot fully activate, multiply, or produce the inflammatory proteins that drive rejection.
By dampening this response, belatacept also reduces the production of anti-donor antibodies — proteins the body might otherwise make to attack the new kidney. The result is a more controlled immune response that tolerates the transplanted organ.
💊How it's taken▾
Nulojix is given exclusively as a 30-minute intravenous (IV) infusion by a healthcare professional — it is never self-administered at home. Dosing follows two phases:
- Initial phase: Infusions are given on the day of transplant (before the organ is implanted), at approximately day 5, and then at the end of weeks 2, 4, 8, and 12
- Maintenance phase: Starting at the end of week 16, infusions are given once every four weeks (within a 3-day window) on an ongoing basis
The dose is calculated based on your actual body weight at the time of transplant. Higher-than-recommended doses or more frequent dosing are not recommended because they significantly increase the risk of serious brain infections and lymphoma. Always keep your infusion appointments and follow your transplant team's schedule exactly.
🤒Side effects — in detail▾
The most commonly reported side effects — occurring in at least 1 in 5 patients — include:
- Anemia (low red blood cell count, which can cause fatigue)
- Diarrhea
- Urinary tract infections
- Swelling in the legs or feet (peripheral edema)
- Constipation
- High blood pressure (hypertension)
- Fever (pyrexia)
- Nausea and vomiting
- Headache
- Low or high potassium levels (hypokalemia or hyperkalemia)
- Low white blood cell count (leukopenia)
- Cough
More serious reactions — including lymphoma (PTLD), brain infections such as PML, and other opportunistic infections — require immediate medical attention; contact your transplant team right away if you notice any new neurological symptoms, signs of serious infection, or unexplained lumps or growths.
⚠️Warnings & precautions▾
- PTLD (post-transplant lymphoproliferative disorder): Nulojix raises the risk of this abnormal lymph cell growth, which most often affects the brain. Risk is highest in EBV-negative patients (who must not receive this drug) and with higher-than-recommended doses. Watch for changes in thinking, memory, or behavior.
- Progressive multifocal leukoencephalopathy (PML): A rare, often fatal brain infection caused by the JC virus. Two fatal cases were reported in clinical trials with higher-than-recommended doses. Report any new neurological, cognitive, or behavioral symptoms immediately.
- Serious infections: Bacterial, viral (including CMV, herpes, and tuberculosis), fungal, and protozoal infections are all more common. Some have been fatal. Preventive treatment for CMV and Pneumocystis is recommended. Screen and treat for latent tuberculosis before starting.
- Other cancers: Immunosuppression increases risk of skin cancer and other malignancies. Limit sun and UV exposure; use sunscreen and protective clothing.
- Polyoma virus nephropathy (PVAN): BK virus infection can damage the transplanted kidney and lead to graft loss. Your team will monitor for this.
- Liver transplant: Not recommended — associated with increased graft loss and death.
- Live vaccines: Must be avoided during treatment.
- Corticosteroid minimization: Reducing steroids too aggressively after transplant has been associated with increased acute rejection, including severe (Grade III) rejection and graft loss. Follow your team's corticosteroid plan closely.
- Anti-thymocyte globulin timing: If given at the same time as the first belatacept dose, there is a risk of dangerous blood clots forming in the blood vessels of the transplanted kidney. A gap of at least 12 hours between the two is suggested.
🔀What it interacts with▾
Nulojix has a few important drug interactions to be aware of:
- Mycophenolate mofetil (MMF): Nulojix allows higher levels of MMF's active form (mycophenolic acid) in the blood compared to cyclosporine. If you switch between cyclosporine and Nulojix, your MMF dose may need to be adjusted to avoid too much or too little immunosuppression.
- Anti-thymocyte globulin (and other cell-depleting induction agents): Giving these at the same time as the first Nulojix infusion may increase the risk of blood clots in the transplanted kidney's blood vessels — a 12-hour gap between the two is suggested.
- Live vaccines: Vaccines containing live virus (including nasal flu spray, MMR, varicella, yellow fever, BCG, oral polio, and typhoid TY21a) must not be given while you are on Nulojix — the suppressed immune system cannot safely handle them.
- Most other medications: Nulojix does not appear to affect the blood levels of drugs processed by the common liver enzyme pathways (CYP1A2, CYP2C9, CYP2D6, CYP3A, CYP2C19), so no dose adjustments are generally needed for those drugs.
This is not a complete list of interactions. Always talk with your doctor or pharmacist before starting, stopping, or changing any medication.
📋Before taking it▾
- EBV-negative or unknown status: Nulojix is contraindicated — you must not take it if you have never been exposed to Epstein-Barr virus or if your status is unknown, due to very high risk of a serious brain lymphoma
- Pregnancy: Animal studies suggest belatacept may harm a developing baby. If you are pregnant or planning to become pregnant, discuss risks with your doctor. A pregnancy registry (Transplant Pregnancy Registry International, 1-877-955-6877) is available for monitoring outcomes.
- Breastfeeding: It is not known whether Nulojix passes into human breast milk. The benefits of breastfeeding and the risks to the infant should be weighed carefully with your doctor.
- Children and teenagers (under 18): Safety and effectiveness have not been established; Nulojix is not approved for pediatric use.
- Older adults (65 and older): Nulojix can be used, but close monitoring is warranted — greater sensitivity or reduced effectiveness cannot be ruled out.
- History of tuberculosis or TB exposure: You must be screened and treated for latent TB before starting Nulojix.
- Liver transplant recipients: Nulojix is not recommended due to increased risk of graft loss and death.
- Patients considering switching from calcineurin inhibitor (CNI)-based therapy: Converting stable kidney transplant patients from a CNI-based regimen to belatacept is not recommended unless the patient cannot tolerate CNIs, as it increases the risk of acute rejection.
🚑If you take too much▾
Single doses up to twice the recommended amount have been given to healthy subjects without obvious toxic effects. However, in kidney transplant patients, using higher cumulative doses or more frequent dosing than recommended led to a greater rate of serious central nervous system side effects — including brain infections and lymphoma.
If an overdose is suspected, the patient should be monitored carefully for any signs of adverse reactions and treated supportively as needed.
📡Pharmacodynamics — effects in the body▾
By blocking T cell costimulation, belatacept reduces the immune system's production of inflammatory proteins (cytokines) that drive rejection and also lowers the body's ability to make antibodies against the donor organ. Clinical trials showed that belatacept treatment led to greater reductions in immunoglobulin levels (IgG, IgM, and IgA — proteins the immune system makes) compared to cyclosporine, particularly in the first 6 to 12 months after transplant.
Patients with lower immunoglobulin levels appeared to have a higher incidence of serious infections and CNS complications, which is why the drug's dose and frequency should never be exceeded — more suppression does not mean better outcomes and significantly increases risk.
🔬Pharmacokinetics — how your body processes it▾
Belatacept is given intravenously and reaches peak blood levels at the end of each infusion. It has a terminal half-life (the time it takes for blood levels to fall by half) of roughly 8 to 10 days in both healthy subjects and kidney transplant patients. Body weight influences how quickly the drug is cleared — heavier patients tend to clear it faster — but factors like age, sex, race, kidney function, liver function, and diabetes do not meaningfully affect clearance.
After the initial intensive dosing phase, steady-state blood levels are typically reached by week 8; during the once-monthly maintenance phase, steady state is achieved by month 6. Blood levels remain stable from month 6 through at least three years post-transplant with consistent monthly dosing. Belatacept does not affect the metabolism of most common medications processed by liver enzymes (CYP450 pathways).
📦How to store it▾
NULOJIX lyophilized powder is stored refrigerated at 2°C to 8°C (36°F to 46°F). storing in the original package until time of use. stored under refrigeration conditions: 2°C to 8°C (36°F to 46°F) and protected from light for up to 24 hours (a maximum of 4 hours of the total 24 ho…
📄 Written from Belatacept Injection’s FDA-approved label information, summarized in plain language with AI, and reviewed by our pharmacy team before publication. Every point is grounded in that labeling — nothing is invented. How we use AI →
🩺 Pharmacist Counseling Corner
Quick, plain-English answers to the questions patients ask most about Belatacept Injection — the kind of thing our pharmacy team would talk through with you at the counter.
Why do I need to be tested for EBV before I can take this medication? ▾
How is this medication given — do I inject it myself at home? ▾
What warning signs should make me call my doctor right away? ▾
Can I get vaccines while I'm on Nulojix? ▾
Is it safe to take Nulojix if I'm pregnant or want to become pregnant? ▾
I've heard this medication lowers my immune system — does that mean I'll get sick more often? ▾
Is Belatacept Injection available over the counter? ▾
When was Belatacept Injection first available? ▾
Who makes Belatacept Injection? ▾
💬 Answers drafted from Belatacept Injection’s FDA-approved label information, summarized in plain language with AI, and reviewed by our pharmacy team before publication. Grounded in that labeling — nothing is made up. How we use AI →
🧰 Keep exploring
💊 How Belatacept Injection comes
Belatacept Injection is available in 1 form. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.
Injection
How this form is used
- Nulojix is used intravenously to prevent organ rejection in adult kidney transplant recipients
- Nulojix is used only in patients confirmed to be EBV seropositive (have prior EBV immunity)
- Nulojix is used as part of a combination regimen with basiliximab induction, mycophenolate mofetil, and corticosteroids
- Nulojix is given as an intravenous infusion over 30 minutes by a healthcare professional
- Nulojix must be prepared using only the silicone-free disposable syringe supplied with each vial — do not substitute a different syringe
- Nulojix should be infused through its own IV line and must not be mixed or run at the same time as other intravenous medications
- Nulojix is given more frequently in the weeks after transplant, then reduced to once every four weeks during the maintenance phase — follow your transplant team's exact schedule
📊 Belatacept Injection across the U.S. market
How Belatacept Injection appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.
Share of FDA-listed product records by manufacturer — FDA National Drug Code Directory. Record counts are not sales or prescription volume.
📈 How widely Belatacept Injection is used
A general measure of how commonly Belatacept Injection is prescribed, based on Medicaid — one of the largest public drug programs. The figure below is prescriptions filled in Q1–Q4 2025, summed across every form and brand of the drug.
Think of this as a proxy for how widely Belatacept Injection is used, drawn from freely available public data. Medicaid is just one program — these numbers don’t include Medicare, other government coverage, or commercial and cash-pay prescriptions, so real-world use is higher than what’s shown here.
How commonly is Belatacept Injection prescribed? Of the 1,596 medications we measure, Belatacept Injection ranks #935 by Medicaid prescriptions — more than 41% of them.
Utilization by Belatacept Injection product
Pick a product to see its own Medicaid numbers. Each chip is one clinical product — a specific strength & dosage form as defined by RxNorm — with brand-name and generic versions combined.
belatacept 250 MG Injection
Summed across the 1 of 1 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1112976
Shares are of the Medicaid prescriptions shown here. Product grouping follows RxNorm (the National Library of Medicine’s drug terminology), so “one product” means one strength & dosage form regardless of manufacturer. Dollar figures are gross Medicaid reimbursement before mandatory rebates — rebates (often large, especially for brand-name drugs) are confidential, so actual net cost to Medicaid is lower than shown.
Source: Medicaid State Drug Utilization Data (CMS), aggregated by generic ingredient — summed across every NDC (all brands, strengths, salt forms and dosage forms) of Belatacept Injection, and across all states and both fee-for-service and managed-care claims. A general popularity signal; it excludes Medicare, commercial insurance and cash prescriptions, so it is not total U.S. use. Based on the 1 of 1 listed Belatacept Injection NDCs with Medicaid activity.
🔍 Compare Belatacept Injection products
A representative set of FDA-listed product records for Belatacept Injection — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)
| Strength | Route | Manufacturer / Labeler | Category ⓘ | Details |
|---|---|---|---|---|
| 💊Injection | ||||
| 250 mg | Intravenous | E.R. Squibb & Sons, L.L.C. × 2 listings | BLA | View NDC → |
| 1 kg/kg | — | Lotte Biologics USA, LLC | BULK INGREDIENT | View NDC → |
Showing 3 of 3 products — FDA National Drug Code Directory. See every product, package size and price: browse all 3 Belatacept Injection NDCs →
📈 What people report — real-world data (FDA FAERS)
After a medicine reaches the market, patients, doctors and drugmakers can send the FDA reports of problems they think may be linked to it. Here’s what’s been reported for Belatacept Injection — a signal of what to watch for, not proof the drug caused it.
Source: openFDA, from the FDA Adverse Event Reporting System (FAERS). These are voluntary reports — they don’t prove the drug caused the effect, and counts reflect how often something was reported, not how often it actually happens. Reports also often name the very problem the medicine is taken for — a common reason to file one is that the drug didn’t help — so for a pain reliever you may see “pain” high on the list; that points to why the report was filed, not to the drug causing the symptom. This counts every report that lists Belatacept Injection in any role, so the total runs higher than the FDA’s official dashboard, which counts only cases where the drug is the suspect. For the authoritative figures, see the FDA FAERS Public Dashboard. Always talk to your pharmacist or doctor.
🏛️ The road to your pharmacy
How Belatacept Injection went from FDA review to the pharmacy shelf — the key milestones in its regulatory journey.
Source: Drugs@FDA.
🚨 Recall history
A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.
Source: openFDA drug enforcement (recall) reports.
RxNorm Concept Web — From Ingredient to Every Form and Strength
This page starts with one ingredient concept (IN). The branches below show its dose-form concepts (SCDF), then the available clinical drug and strength concepts (SCD). Combination products remain separate concepts with their own pages.
RxCUI 1112973 1 dose form · 1 strength
-
Dose form (SCDF) Injection RxCUI 1804971In current FDA listingsClinical drug / strength (SCD) 250 MGRxCUI 1112976
Look up RxCUI 1112973 in the RxCUI Atlas →
RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.
📦 Supply & shortage status
Whether Belatacept Injection is in short supply in the U.S. right now, plus any shortage history the FDA has on record. A shortage usually reflects a manufacturing or demand issue — not a safety problem with the drug.
Source: openFDA, from the FDA Drug Shortages database.
🏷️ Sold under these brand names
🏭 Manufacturers & labelers
RxNorm drug class
Belatacept Injection belongs to the Selective T Cell Costimulation Blocker class.
Classified by RxNorm RxClass — the U.S. National Library of Medicine's standardized drug-classification service (Established Pharmacologic Class from the FDA, the ATC drug family from the WHO, and mechanism of action). Reference only, not medical advice.
🔬 Where this comes from
Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.
How we combine label and product data
HelloPharmacist combines public FDA and NLM records; we don’t author the underlying clinical facts. We identified 1 FDA-filed SPL label set within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. The representative label is the starting point for the displayed reference monograph; the 12 largest stored in-scope SPL records, which may include that representative, are compared section by section, and the longest available version of each section is retained. Forms, routes, brands, labelers, product-listed strengths, and product-record counts are aggregated separately from ingredient-matched FDA NDC Directory records; package records listed above are associated with the linked SPL; and the normalized concept hierarchy comes from NLM RxNorm.
Where a section is identified as AI-written, its plain-language text is generated from bounded label evidence. New draft drug pages remain in the admin review queue before first publication. E.R. Squibb & Sons, L.L.C. is the representative DailyMed label linked for verification and dates; it is not the sole source used for the page.
This is general education, not medical advice — always consult your doctor or pharmacist about your medications and any medical condition. For the exact wording of the linked representative label, view that label on DailyMed; some displayed composite sections may come from other in-scope SPL labels. Learn how we use AI and our data sources & update cadence.